Pax-3 is a member of the Pax family of transcription factors involved in transcriptional control events during embryonic development. Here we report a functional dissection of the Pax-3 protein and describe the protein domains which are responsible for different activities. A transcription inhibition activity is located in the rst 90 N-terminal amino acids and includes part of the paired domain. Furthermore, the C terminus of Pax-3 is able to confer transcriptional activation of basal promoters. Pax-3 can utilize both transcription modulating functions and activates transcription over a narrow range of protein concentration in the presence of promoter elements containing functional binding sites.
Pax-3 is expressed early during embryonic development in spatially restricted domains in the nervous system and in some mesodermally derived structures (1) . The expression pattern ofPax-3 suggests that it plays an important role in the regional specification of certain aspects of the nervous system. Recently, this hypothesis has been confirmed as mutations in the Pax-3 gene were found to be responsible for the splotch (sp) phenotype in mice (2) (3) (4) (5) and the Waardenburg syndrome type 1 (WS1) in humans (6) (7) (8) (9) (10) . Furthermore, a chromosomal translocation of PAX3 (the human homolog of mouse Pax-3; ref. 11 ) is implicated in the generation of the pediatric solid tumor alveolar rhabdomyosarcoma (12, 13) . Finally, several Pax gene products, including Pax-3, have been shown to induce transformation of cells in culture, and these Pax-transformed cells can subsequently induce tumors in recipient mice (14) .
The Pax-3 protein (479 amino acids long) contains two different DNA-binding domains, a paired domain (PD) and a paired-type homeodomain (HD). An octapeptide sequence motif that is conserved among most PD-containing proteins is located between the PD and the HD. Pax-3 binds in vitro to a DNA sequence derived from the Drosophila even skipped promoter (1, 15) . This sequence contains an upstream ATTA motif recognized by the HD and a downstream paired domain recognition site (PRS), either GTTCC (PRS-1) or GTTAC (PRS-9), bound by the PD (15) . Efficient binding of Pax-3 to the PRS sequences requires the presence of both DNA recognition motifs (ATTA and either GTTCC or GT-TAC), suggesting a synergistic interaction of the two DNAbinding domains with the PRS sequences. The length of the spacer sequence between the ATTA and GTTCC motifs can vary considerably without affecting the binding of Pax-3 (16) . In addition, the space between the PD and the HD (53 amino acids) can be shortened without changing the flexibility of Pax-3 to interact with the PRS sequences (16) . Finally, the protein region between the PD and the HD was found to participate in the homodimerization of truncated Pax-3 protein products when bound to the DNA (15) . In this work, we describe the dissection of the Pax-3 protein functions and ascribe specific functional activities, such as transcription inhibition and activation, to discrete domains of Pax-3. When PRSs are inserted in front of a minimal promoter, Pax-3 can utilize these sequences to modulate the transcription rate of a linked reporter gene. Lower Pax-3 concentrations activate transcription, whereas higher concentrations inhibit the basal promoter activity in cell culture experiments. These data suggest that Pax-3 may be a bifunctional transcriptional regulatory protein.
MATERIALS AND METHODS
Recombinant Plasmids. The plasmids RF1-Pax3 and pS1-Pax3 (15) were the starting plasmids used to generate all Pax-3 deletion mutants. Numbers in the parentheses refer to the nucleotide positions on the Pax-3 cDNA (1) . The HincII(408)-Xba I, Stu I(442)-Xba I, and Nco I(534)-Xba I fragments were blunt-ended and subcloned into the Sac I (blunt-ended with T4 DNA polymerase) site ofpSl-Pax3. The Xba I site of the fragments was always cloned into the Xba I site of the vector. The BamHI-HindIII fragments of these constructs were then subcloned into the BamHI/HindIII sites of RF1-Pax3 to create A-Hinc, A-Stu, and A-Nco. BamHI and Cla I(858) restriction digestion of RF1-Pax3, treatment with the Klenow fragment of DNA polymerase I, and religation led to A-Cla. A-Sma lacks the internal Sma I fragment (342-673). The BamHI-Pvu 11(985) and BamHIPvu 11(1213) fragments from RF1-Pax3 were subcloned into the BamHI/Sma I sites of pSl and the resulting BamHI-Xba I fragments were introduced into the BamHI/Xba I sites of pEVRF1 to generate Pvul-A and Pvu2-A. The BamHI-Pvu II(1578) fragment from RF1-Pax3 was subcloned into the BamHI/Sma I sites of pSl. The Pax-3 cDNA fragment was then excised by digestion with BamHI and Dra I and subcloned into the BamHI/Pvu II(1844) sites of RF1-Pax3 to generate Pvu3-A. A 33-bp DNA fragment from the polylinker region of pSl (5'-CTGATCCGTCGACGGTACCCCGGG-GAATTCGAG-3') was inserted into the HindIII(1065) site in RF1-Pax3 to introduce 11 amino acids (Leu-Ile-Arg-Arg-ArgTyr-Pro-Gly-Glu-Phe-Glu) between the lysine and leucine in the turn of the helix-turn-helix motif of the Pax-3 HD and to create Pax3-MHD. Pax3-Moct was constructed by introducing 9 bp into the Cla I(858) site of RF1-Pax3 (5'-CGAATTCCC-3'), which then introduces three additional amino acids (Glu-Phe-Pro) between the isoleucine and aspartic acid in the Pax-3 octapeptide. The reporter plasmid 17M2-TK-CAT was kindly provided by P. Chambon (17) NIH 3T3 cells were transfected in 60-mm dishes (approximately 30% confluent) by using the calcium phosphate method. Calcium phosphate/DNA precipitate was formed in a volume of 0.7 ml containing a total of 14 ,g of DNA. Plates were rinsed with medium, the precipitate was added to the plate, and cells were incubated for 30 min at 37°C in 5% C02/95% air. Medium (4 ml) containing 50 mM chloroquine was added to the plates, and cells were incubated an additional 5 h at 37°C. After the medium had been changed again, cells were maintained in culture until they were harvested about 60 h after transfection. Each experiment was repeated at least four times and the variation between experiments was about 5%. A significant variation of about 20% was observed in the experiment described in Fig. 3 . COS-7 cells were transfected in 90-mm tissue culture dishes with 15 ,ug of the different expression constructs by using the DEAE-dextran method. Preparation of whole-cell extracts and gel mobility shift assays were performed as previously described (21) .
RESULTS
Inhibition of the N-CAM Promoter Basal Activity by Pax-3. Recently, it has been suggested that N-CAM could be a candidate target gene for Pax-3 regulation (2, 22) . N-CAM and Pax-3 have overlapping expression patterns in the neural tube during mouse embryogenesis (1, 23) . In addition, there appear to be significant differences in both the level of N-CAM expression and the types of N-CAM polypeptides produced in the neuroepithelium of Sp/Sp homozygous mouse embryos as compared with wild-type embryos (22) .
To test whether Pax-3 could affect the activity of the N-CAM promoter, we performed transient transfection experiments in NIH 3T3 fibroblasts. The reporter gene plasmid constructs contained various lengths of upstream sequences from the N-CAM gene (19, 20) fused to the bacterial CAT gene. In parallel with Pax-3, we also tested the effects of Pax-1, Pax-8, and Pax-6 in separate assays ( Fig. 1 A and C) . Fig. 1C To determine how the effect ofPax proteins on the N-CAM promoter is mediated, we dissected the promoter region (from -650 to +53) into short DNA fragments and assayed these for binding to Pax proteins in gel shift assays (Fig. 1D) . A 128-bp DNA segment (nucleotide -140 to nucleotide -12) located upstream of the translation initiation ATG codon of the mouse N-CAM gene and downstream from the transcription start sites (see Fig. 1B, boxed area) , was specifically bound by Pax-1, Pax-8, Pax-6, and the truncated Pax-3 protein, Pvul-A, which contains the intact PD ( Fig. 2A) , but not by the wild-type Pax-3 or the Pax-3 splotch variant Pax-3/Sp (15) . Thus, Pax-3 is able to inhibit N-CAM promoter activity, yet direct binding to the promoter region was not detected. To demonstrate the Pax-3 DNA-binding activity in the extracts that we used in the experiments with the N-CAM promoter, we performed gel mobility shift assays using the same extracts and the PRS-1 oligonucleotide as template. The PRS-1 sequence is derived from the Drosophila even skipped promoter and was shown to bind Pax-3 and other PD-containing proteins (15, 21) . The PRSs are designated by numbers (21) . Fig. 2C shows the sequences of PRS-1 and PRS-9, which both bind Pax-3 with similar affinities (15) . In the following experiments we compared the binding of the wild-type Pax-3 with the binding properties of some Pax-3 truncated derivatives ( Fig. 2A) in qualitative gel shift assays. As shown in Fig. 2B , the fulllength Pax-3 protein binds to the PRS-1 sequence. The mutant A-Hinc, which lacks five amino acids at the N terminus of the PD, is still able to bind PRS-1, whereas further deletions into the PD abolish DNA binding. C-terminal deletions and the insertion of three amino acids within the conserved octapeptide (Pax3-Moct) do not affect the PRS-1 DNA binding. Interestingly, a Pax-3 mutant containing an insertion of 11 amino acids within the turn of the HD (Pax3-MHD) is still able to bind PRS-1 DNA. These results suggest that the PD of Pax-3 is essential for the sequencespecific binding ofDNA. N-terminal deletions were sufficient to disrupt binding of Pax-3 to the PRS-1 sequence. No stable protein-DNA complexes could be detected even though these N-terminal deletions contained an intact HD and the recognition sequence contained an ATTA motif.
Pax-3 Concentration-Dependent Transcriptional Activation and Mapping of the Pax-3 Transcription-Modulating Domains. Since the effect of Pax-3 on the transcription of the N-CAM promoter in cell culture experiments was not specific, we assayed specific transcriptional modulation by the Pax-3 protein by cotransfecting NIH 3T3 cells with a reporter gene plasmid construct carrying six copies of PRS-9 (see Fig. 2C for the sequence ofPRS-9) attached to the TK-CAT gene, and increasing amounts of the Pax-3 expression vector (Fig. 3) . PRS-9 (like PRS-1) can be specifically bound by Pax-3 (15) and thereby serve as a specific reporter to study transcrip- (Fig. 2C) fected effector plasmid decreased CAT activity. In contrast, the profile of transcriptional modulation by using a mutated PRS-reporter construct that cannot bind Pax-3 shows a gradual decrease in the CAT transcription with increasing amounts of cotransfected Pax-3 expression vector (data not shown). These data suggest that in the presence of functional PRS promoter elements, Pax-3 functions as a transcriptional activator over an unusually narrow concentration range, whereas Pax-3 concentrations above this narrow range inhibit transcription nonspecifically.
To map the domains of Pax-3 that are involved in transcription modulating activities, the full-length protein or various portions of the Pax-3 protein (Fig. 4A) (17) .
Analysis of the CAT activity in NIH 3T3 fibroblasts cotransfected with various GAL4 fusion proteins and the reporter gene plasmid revealed an inhibition of the reporter gene basal transcriptional activity in all constructs that included the N-terminal region of Pax-3 (Fig. 4B) . The intact continuous segment of the first 90 amino acids of Pax-3 (GAP3-NK) displays a strong transcription-inhibiting activity. This region includes 57 amino acids ofthe PD and the first a-helix. A slight decrease in basal CAT activity was also detected when effector plasmids that express part of (GAP3-CP1) or the complete HD (GAP3-CP2) were used. Whereas no transcriptional stimulation was evident with GAL4 chimeric proteins containing the PD or the HD, significant stimulation of basal CAT activity was obtained with the GAP3-KB fusion protein, which contains the last 78 C-terminal amino acids ofPax-3. This indicates that the C terminus contains a transcription-activating domain when transferred to a heterologous protein. (Fig. 1A) . Since the PD sequences are highly conserved among the Pax proteins, it will be ofinterest to test whether fusion of these 33 amino acids to other Pax proteins can confer transcription-inhibiting activity to them. Nevertheless, searching the protein data base with the Pax-3 transcription-inhibiting domain did not reveal any significant homology to other proteins except the PD homologs.
DISCUSSION
Proc. Natl. Acad. Sci. USA 91 (1994) Proc. Natl. Acad. Sci. USA 91 (1994) 12749 Pax-3 also inhibits the basal transcription of N-CAM reporter constructs in cellular cotransfection experiments. Since we observe no binding by the native Pax-3 protein in our studies, we cannot establish that N-CAM is a target gene of the wild-type Pax-3 protein. Thus, transcription inhibition by Pax-3 may be due to "squelching" through destabilization or inhibition of the formation of preinitiation complexes, thereby interfering with the interactions between positively acting transcription factors and the general transcription machinery (24, 25) . However, we have shown that the Pvul-A protein, which contains the intact PD of Pax-3 and is very similar to the splotch Sp2H Pax-3 protein product (2) , can bind to the N-CAM promoter. Thus, since the PD of Pax-3 can bind to the N-CAM promoter, we cannot exclude the possibility that the wild-type Pax-3 can also bind to the N-CAM promoter under other (and perhaps even physiological) conditions, by stabilizing its DNA binding through interaction with other accessory proteins. Since Pax-1, Pax-6, and Pax-8 were shown to bind the N-CAM promoter, it is a compelling prospect that N-CAM is a downstream target of these Pax gene products.
We have also defined a transcription-activating domain in the Pax-3 protein that includes the 78 C-terminal amino acids. It is rich in proline and also in serine and threonine and it resembles the activating domains ofOct-2 (26) and CTF-1 (27 Fig. 4 suggest that different concentrations of Pax-3 can specify its transcriptional effector function. Low amounts of Pax-3 expression plasmid lead to transcriptional activation, whereas high amounts result in inhibition. These different responses are elicited over a narrow concentration range, as a 2-fold increase in Pax-3 levels above the threshold level is sufficient to convert a stimulated form to a repressed one and vice versa. Thus, predetermined thresholds of Pax-3 may be involved in establishing cell fate in vivo, which may then be changed by slightly increasing or decreasing the level of Pax-3.
